The pathogenesis, diagnosis and treatment of Raynaud phenomenon

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature Reviews Rheumatology

• Publication date

  2012-07-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrrheum.2012.96PMID 22782008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon

  2012cited by this paper
• [Raynaud's phenomenon].

  2011cited by this paper
• Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis

  2011cited by this paper
• Platelet-derived serotonin links vascular disease and tissue fibrosis

  2011cited by this paper
• Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.

  2011cited by this paper
• The association of Raynaud’s syndrome with rheumatoid arthritis—a meta-analysis

  2011cited by this paper
• Contemporary management of Raynaud's phenomenon and digital ischaemic complications

  2011cited by this paper
• Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.

  2010cited by this paper
• Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

  2010cited by this paper
• Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis.

  2010cited by this paper
• Thumb Involvement in Raynaud’s Phenomenon as an Indicator of Underlying Connective Tissue Disease

  2010cited by this paper
• Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

  2010cited by this paper
• Vascular Disease in Scleroderma

  2010cited by this paper
• Phosphodiesterase inhibitors in the management of autoimmune disease.

  2010cited by this paper
• Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study.

  2010cited by this paper
• Mechanisms and Modulators of Temperature Regulation Local thermal control of the human cutaneous circulation

  2010cited by this paper
• Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy.

  2010cited by this paper
• Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study

  2010cited by this paper
• Local ascorbate administration inhibits the adrenergic vasoconstrictor response to local cooling in the human skin.

  2010cited by this paper
• Assessing microvascular changes in systemic sclerosis diagnosis and management

  2010cited by this paper
• Cellular and molecular aspects of vascular dysfunction in systemic sclerosis

  2010cited by this paper
• Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans.

  2010cited by this paper
• Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis

  2010cited by this paper
• Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions

  2010cited by this paper
• Botox Therapy for Ischemic Digits

  2009cited by this paper
• A Meta-Analysis

  2009cited by this paper
• Long-term results of periarterial sympathectomy.

  2009cited by this paper
• EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

  2009cited by this paper
• Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders.

  2009cited by this paper
• Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study

  2009cited by this paper
• Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients.

  2009cited by this paper
• MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.

  2009cited by this paper
• The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis.

  2009cited by this paper
• Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud’s Phenomenon Secondary to Systemic Sclerosis

  2009cited by this paper
• Correlation of Biomarkers of Endothelium Dysfunction and Matrix Remodeling in Patients with Systemic Sclerosis

  2009cited by this paper
• The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

  2009cited by this paper
• Vascular Disease in Scleroderma

  2009cited by this paper
• Faculty Opinions recommendation of Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

  2009cited by this paper
• Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

  2008cited by this paper
• Vascular disease in scleroderma: mechanisms of vascular injury.

  2008cited by this paper
• Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.

  2008cited by this paper
• Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon.

  2008cited by this paper
• Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population

  2008cited by this paper
• Raynaud's phenomenon (secondary).

  2008cited by this paper
• Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database

  2008cited by this paper
• Raynaud's phenomenon (secondary).

  2008cited by this paper
• Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited

  2008cited by this paper
• The pathology of scleroderma vascular disease.

  2008cited by this paper
• Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients.

  2008cited by this paper
• Maximum blood flow and microvascular regulatory responses in systemic sclerosis.

  2007cited by this paper
• Sparing of the thumb in Raynaud's phenomenon.

  2007cited by this paper
• Commentary. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease. Results of ten years of prospective surveillance.

  2007cited by this paper
• Office capillaroscopy in systemic sclerosis

  2007cited by this paper
• Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.

  2007cited by this paper
• Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al.

  2007cited by this paper
• Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries.

  2007cited by this paper
• Platelet contributions to the pathogenesis of systemic sclerosis

  2007cited by this paper
• The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon.

  2007cited by this paper
• Management of Vasospastic Disorders with Botulinum Toxin A

  2007cited by this paper
• Selective and mixed endothelin receptor antagonism in cardiovascular disease.

  2007cited by this paper
• Increased circulating platelet–leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study

  2007cited by this paper
• Reduced circulating levels of angiotensin-(1–7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control

  2007cited by this paper
• Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study

  2006cited by this paper
• Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin.

  2006cited by this paper
• Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.

  2006cited by this paper
• Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis

  2006cited by this paper
• Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population.

  2006cited by this paper
• Variations of neuronal nitric oxide synthase in systemic sclerosis skin.

  2006cited by this paper
• Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis.

  2006cited by this paper
• Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?

  2006cited by this paper
• Stroke Among Patients With Dizziness, Vertigo, and Imbalance in the Emergency Department: A Population-Based Study

  2006cited by this paper
• Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.

  2006cited by this paper
• Hemorheologic profile in systemic sclerosis: role of NOS3 -786T > C and 894G >T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease.

  2006cited by this paper
• Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy

  2005cited by this paper
• Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis

  2005cited by this paper
• Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.

  2005cited by this paper
• Novel Fibrogenic Pathways Are Activated in Response to Endothelial Apoptosis: Implications in the Pathophysiology of Systemic Sclerosis1

  2005cited by this paper
• Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon.

  2005cited by this paper
• Pathogenesis of Raynaud's phenomenon.

  2005cited by this paper
• Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries.

  2005cited by this paper
• The incidence and natural history of Raynaud's phenomenon in the community.

  2005cited by this paper
• Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

  2004cited by this paper
• Rho Kinase Mediates Cold-Induced Constriction of Cutaneous Arteries: Role of &agr;2C-Adrenoceptor Translocation

  2004cited by this paper
• Laser Doppler imaging: a developing technique for application in the rheumatic diseases.

  2004cited by this paper
• Defective vasculogenesis in systemic sclerosis.

  2004cited by this paper
• Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans.

  2004cited by this paper
• Efficacy and tolerability of a selective α2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study

  2004cited by this paper
• Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease.

  2004cited by this paper
• Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.

  2004cited by this paper
• Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis.

  2002cited by this paper
• Clinical practice. Raynaud's Phenomenon.

  2002cited by this paper
• Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells.

  2001cited by this paper
• Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: A description of treatment protocol and evaluation of results

  2001cited by this paper
• Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.

  2001cited by this paper
• Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

  2001cited by this paper
• The pilot study.

  2000cited by this paper
• Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma.

  2000cited by this paper
• Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries.

  2000cited by this paper
• A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon.

  2000cited by this paper
• Macrovascular disease and systemic sclerosis

  2000cited by this paper

• Beyond Raynaud's: Atypical Peripheral Vascular Manifestations in a Case of CREST Syndrome

  2026cites this paper
• Cigarette smoke extract induces p38-mediated expression and ROS/rho-mediated translocation of alpha 2C adrenoceptor in human microvascular smooth muscle cells.

  2025cites this paper
• Low-Dose Sublingual Ketamine for the Treatment of Raynaud's Phenomenon

  2025cites this paper
• Temporal trends in vascular medication use in 8,079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort.

  2025cites this paper
• Sudden Hand Color Changes in a Young Man.

  2025cites this paper
• Lower environmental temperature and higher relative humidity had significant associations with worsened Raynaud phenomenon in systemic sclerosis: comment on the article by Taylor et al

  2025cites this paper
• Collagen IV and laminin-1 as key macromolecules in ocular structure and pathology: A review.

  2025cites this paper
• The N-of-1 Trials and where to use them in Rheumatology

  2025cites this paper
• Ethosuximide Induced Raynaud's Phenomenon in a Child With Childhood Absence Epilepsy

  2025cites this paper
• Factors associated with diagnostic delay and specialty consultation patterns in systemic sclerosis: A cross-sectional study

  2025influential citation
• Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database.

  2025cites this paper
• Reply

  2025cites this paper
• Cold Fingers Under the Lens: Unveiling Microvascular Differences Between Children with Primary Raynaud's Phenomenon and Healthy Individuals.

  2025cites this paper
• Cold responses and hormonal echoes: a comprehensive view of Raynaud’s vascular dysfunction

  2025cites this paper
• Knockdown of LncRNA MEG3 promotes damage of vascular endothelial cells induced by vibration

  2025cites this paper
• Quality and Reliability of Raynaud’s Phenomenon Information on YouTube: A Cross-Sectional Study

  2025cites this paper
• Systemic Sclerosis Presenting as Osteomyelitis of the Finger: Physicians Must Maintain a High Index of Suspicion for Systemic Sclerosis when Evaluating Patients with Fingertip Ulceration or Infection

  2025cites this paper
• Infrared thermography for the diagnosis and monitoring of Raynaud’s phenomenon: current evidence and future directions

  2025cites this paper
• Small Devices, Large Changes: Investigating the Impact of a University-Government 3D-Printed Assistive Technology Program on Residents with Disabilities

  2025cites this paper
• Unveiling the Enigma: Idiopathic Digital Infarction—A Case Report and Literature Review

  2025cites this paper
• Resting energy expenditure differs among individuals with different levels of perceived thermal sensitivity: A cross-sectional study

  2024cites this paper
• Raynaud phenomenon: from GWAS to drug repurposing

  2024cites this paper
• Raynaud’s Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment

  2024cites this paper
• Ongyeong-tang for Cold Hypersensitivity in Lower Abdomen, Hands, and Feet: A Case Report

  2024cites this paper
• Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy

  2024cites this paper
• The Efficacy and Tolerability of Prostaglandin Analogues in Treating Systemic Sclerosis-Associated Raynaud Phenomenon: A Systematic Review and Meta-Analysis

  2024cites this paper
• Vascular, Soft Tissue, and Musculoskeletal Imaging in Systemic Sclerosis.

  2024cites this paper
• Preclinical and Clinical Data on Current Therapeutic Options for Micro- and Macrovascular Abnormalities in Systemic Sclerosis

  2024influential citation
• Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.

  2024cites this paper
• Raynaud's phenomenon involving the tongue

  2024cites this paper
• Raynaud’s phenomenon associated with psoriatic arthritis

  2024cites this paper
• Could Gas6/TAM Axis Provide Valuable Insights into the Pathogenesis of Systemic Sclerosis?

  2024cites this paper
• Effect of Betablockers on the Course of Martorell Hypertensive Ulcers: A Retrospective Study

  2024cites this paper
• Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes

  2024cites this paper
• Genetic and functional analysis of Raynaud’s syndrome implicates loci in vasculature and immunity

  2024cites this paper
• Kaposiform hemangioendothelioma presented with raynaud phenomenon: a case report

  2023cites this paper
• Cold Hands or Feet: Is It Raynaud's or Not?

  2023cites this paper
• The alpha-2A-adrenergic receptor (ADRA2A) modulates susceptibility to Raynaud's syndrome

  2023cites this paper
• Necrotizing Raynaud's phenomenon after recurrent COVID-19 infection

  2023cites this paper
• Regulation of MicroRNA Expression in Scleroderma and Idiopathic Pulmonary Fibrosis: A Research Study

  2023cites this paper
• Simultaneous bilateral distal venous arterialization between redial artery and cephalic vein in dorsal hand for Raynaud's phenomenon in both hands: A case report

  2023influential citation
• Effect of Hand Dominance on Radial Artery Spasm and Occlusion: A Prospective Observational Study

  2023cites this paper
• Estrogen receptor and the gender bias in Raynaud's phenomenon.

  2023cites this paper
• Prevalence of Raynaud’s phenomenon in patients with peripheral neuropathy

  2023cites this paper
• A Case Report of Multimodal Analgesia for the Treatment of Refractory Chronic Nipple Pain.

  2023cites this paper
• Fulminant myocarditis in a young woman with mixed connective tissue disease: a case report

  2023cites this paper
• Treatment of Vascular Complications in Systemic Sclerosis: What Is the Best Approach to Diagnosis and Management of Renal Crisis and Digital Ulcers?

  2023cites this paper
• Examining the role of self-reported somatosensory sensations in body (dis)ownership: A scoping review and empirical study of patients with a disturbed sense of limb ownership.

  2023cites this paper
• Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases.

  2023cites this paper
• A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis

  2022cites this paper
• The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self‐controlled trial

  2022cites this paper
• Serum vitamin B12 and D levels in children with Primary Raynaud Phenomenon: a retrospective cohort study

  2022cites this paper
• Cold-induced Vascular Changes in the Macula, Optic Disc and Choroid in Children with Raynaud’s Phenomena

  2022influential citation
• Raynaud’s Phenomenon: Reviewing the Pathophysiology and Management Strategies

  2022cites this paper
• Evaluation of thermal sensitivity is of potential clinical utility for the predictive, preventive, and personalized approach advancing metabolic syndrome management

  2022cites this paper
• Sklerodermie – „die harte Haut“

  2022cites this paper
• Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art

  2022cites this paper
• NADPH-derived ROS generation drives fibrosis and endothelial-to-mesenchymal transition in systemic sclerosis: Potential cross talk with circulating miRNAs

  2022cites this paper
• The receptor for advanced glycation endproducts: A potential role in systemic sclerosis

  2022cites this paper
• Aptamer proteomics of serum exosomes from patients with Primary Raynaud’s and patients with Raynaud’s at risk of evolving into Systemic Sclerosis

  2022cites this paper
• G protein estrogen receptor as a potential therapeutic target in Raynaud’s phenomenon

  2022cites this paper
• Lingual Raynaud’s phenomenon: a rare presentation

  2022cites this paper
• A case of Raynaud’s phenomenon in Arizona, USA

  2022cites this paper
• Placebo response in Raynaud's Phenomenon clinical trials: The prominent role of regression towards the mean: Placebo response in Raynaud's Phenomenon.

  2022cites this paper
• Nailfold capillaroscopy: tips and challenges

  2022cites this paper
• A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s

  2022cites this paper
• Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series

  2022cites this paper
• Advances in the Treatment of Systemic Sclerosis

  2022cites this paper
• Management of Raynaud’s Syndrome following local anesthesia in dentistry

  2022cites this paper
• Treatment of resistant Raynaud's phenomenon with single-port thoracoscopic sympathicotomy: One-year follow-up.

  2022cites this paper
• Quantitative Characterization of Age-Related Changes in Peripheral Vessels of a Human Palm Using Raster-Scan Optoacoustic Angiography

  2022cites this paper
• Standardized nailfold capillaroscopy in children with rheumatic diseases: a worldwide study

  2022cites this paper
• Structural abnormalities associated with glaucoma using swept-source optical coherence tomography in patients with systemic sclerosis

  2021cites this paper
• Correlation between the infrared thermogram and microvascular abnormalities of the nailfold in patients with systemic sclerosis

  2021cites this paper
• Peripheral vasoreactivity in acute ischemic stroke with hemiplegia

  2021cites this paper
• Convolutional Neural Networks for Differential Diagnosis of Raynaud’s Phenomenon Based on Hands Thermal Patterns

  2021cites this paper
• Rheumatologic disorders in patients undergoing esophageal manometry: prevalence, symptom characteristics, and manometric findings.

  2021cites this paper
• Characteristic Features of Infrared Thermographic Imaging in Primary Raynaud’s Phenomenon

  2021cites this paper
• Infrared Thermography as a Method of Verification in Raynaud’s Phenomenon

  2021cites this paper
• What are the effects of vasodilators in patients with primary Raynaud’s phenomenon? A Cochrane review summary with commentary

  2021cites this paper
• Autonomic nervous system activity in primary Raynaud's phenomenon: Heart rate variability, plasma catecholamines and [123I]MIBG heart scintigraphy

  2021cites this paper
• Utilities of Botulinum Toxins in Dermatology and Cosmetology

  2021cites this paper
• Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review.

  2021cites this paper
• Detection of microvascular changes in systemic sclerosis and other rheumatic diseases

  2021cites this paper
• A case of Raynaud's phenomenon of toes induced by whole‐body warm stimulation

  2021cites this paper
• Impact of global warming on Raynaud’s phenomenon: a modelling study [version 1; peer review: 2 approved]

  2021cites this paper
• Management of severe Raynaud's Phenomenon secondary to autoimmune vasculopathy in a young woman

  2021cites this paper
• Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

  2021cites this paper
• Botulinum Toxins in Medical and Cosmetic Dermatology

  2021cites this paper
• Occupational noise exposure and Raynaud’s phenomenon: a nested case–control study

  2021cites this paper
• Raynaud’s phenomenon in the endocrinologist’s practice

  2020cites this paper
• Update on Treatment of Antisynthetase Syndrome: A Brief Review

  2020cites this paper
• Raynaud's phenomenon.

  2020cites this paper
• Clinical impact of nailfold capillaroscopy in daily clinical practice

  2020cites this paper
• Raynaud Phenomenon: Diagnosis and Management

  2020influential citation
• Impact of global warming on Raynaud’s phenomenon: a modelling study

  2020cites this paper
• Diagnosis and treatment lung damage in systemic scleroderma

  2020cites this paper
• Possible piracetam-induced Raynaud's phenomenon in a male patient

  2020cites this paper
• Laser Doppler imaging evaluation of nitroglycerin patch application in systemic sclerosis patients

  2020cites this paper
• Low body weight and involuntary weight loss are associated with Raynaud’s phenomenon in both men and women

  2020cites this paper